- Home
- PHR
PHR
Phreesia Inc.
as 02-21-2025 4:00pm EST
Phreesia Inc is a provider of comprehensive software solutions that improves the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, but not limited to, initial patient contact, registration, appointment scheduling, payments, and post-appointment patient surveys.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | 1.6B | IPO Year: | 2019 |
| Target Price: | $31.07 | AVG Volume (30 days): | 389.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.07 - $30.53 | Next Earning Date: | 03-12-2025 |
| Revenue: | $405,137,000 | Revenue Growth: | 19.91% |
| Revenue Growth (this year): | 18.79% | Revenue Growth (next year): | 13.74% |
Stock Insider Trading Activity of Phreesia Inc. (PHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Roberts Evan | PHR | Chief Operating Officer | Feb 13 '25 | Sell | $30.06 | 19,591 | $588,190.61 | 744,716 | |
| Linetsky David | PHR | SVP, Life Sciences | Feb 13 '25 | Sell | $29.70 | 11,616 | $345,001.01 | 218,135 | |
| Gandhi Balaji | PHR | Chief Financial Officer | Feb 13 '25 | Sell | $30.04 | 33,648 | $1,009,858.50 | 116,174 | |
| Linetsky David | PHR | SVP, Life Sciences | Jan 29 '25 | Sell | $29.68 | 500 | $14,841.00 | 218,135 | |
| VanDuyn Amy Beth | PHR | SVP, Human Resources | Jan 27 '25 | Sell | $27.67 | 3,475 | $95,480.20 | 114,734 | |
| Roberts Evan | PHR | Chief Operating Officer | Jan 27 '25 | Sell | $27.67 | 10,716 | $294,436.36 | 744,716 | |
| Linetsky David | PHR | SVP, Life Sciences | Jan 27 '25 | Sell | $27.67 | 11,685 | $321,060.41 | 218,135 | |
| Hoffman Allison C | PHR | General Counsel & Secretary | Jan 27 '25 | Sell | $27.95 | 12,791 | $357,832.17 | 152,361 | |
| Indig Chaim | PHR | Chief Executive Officer | Jan 27 '25 | Sell | $27.67 | 26,248 | $721,197.87 | 1,268,123 | |
| Gandhi Balaji | PHR | Chief Financial Officer | Jan 27 '25 | Sell | $27.67 | 4,813 | $132,243.60 | 116,174 |
Latest Phreesia Inc. News
PHR Breaking Stock News: Dive into PHR Ticker-Specific Updates for Smart Investing
Simply Wall St.
2 days ago
Phreesia (NYSE:PHR) shareholder returns have been , earning 18% in 1 year
Zacks
8 days ago
Phreesia (PHR) Moves 5.6% Higher: Will This Strength Last?
Insider Monkey
11 days ago
Why Insiders Are Selling Phreesia, Inc. (PHR) Recently
Business Wire
11 days ago
Phreesia’s Sally Thayer Selected as a Top Woman Leader in Software
Business Wire
15 days ago
Phreesia Sets Release Date for Fiscal Fourth Quarter and Fiscal Year 2025 Results
MT Newswires
24 days ago
Phreesia Insider Sold Shares Worth $321,060, According to a Recent SEC Filing
Zacks
24 days ago
Phreesia, Inc. (PHR) Soars to 52-Week High, Time to Cash Out?
Zacks
a month ago
Zacks Industry Outlook Enovis, Omnicell and Phreesia
Compare PHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHR Phreesia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.